NASDAQ · GALT
Healthcare · Biotechnology
$3.53
Up+$0.39 (+12.42%)
Updated Aug 14, 2026, 4:34 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
GALT closed at $3.53 after 21 trading sessions, down 16.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $3.16 | $3.56 | $3.16 | $3.53 | 585.3K |
| Aug 12, 2026 | $3.12 | $3.26 | $3.12 | $3.14 | 231.49K |
| Aug 11, 2026 | $3.13 | $3.15 | $3.02 | $3.13 | 296.15K |
| Aug 10, 2026 | $3.39 | $3.40 | $3.09 | $3.12 | 371.11K |
| Aug 7, 2026 | $3.558 | $3.558 | $3.22 | $3.45 | 329.87K |
| Aug 6, 2026 | $3.13 | $3.25 | $3.07 | $3.22 | 511.18K |
| Aug 5, 2026 | $3.00 | $3.14 | $2.965 | $3.09 | 355.02K |
| Aug 4, 2026 | $2.96 | $3.1233 | $2.72 | $2.985 | 844.24K |
| Aug 3, 2026 | $2.97 | $3.17 | $2.9003 | $3.03 | 296.96K |
| Jul 31, 2026 | $3.26 | $3.335 | $2.955 | $2.97 | 387.7K |
| Jul 30, 2026 | $3.51 | $3.60 | $3.213 | $3.23 | 404.35K |
| Jul 29, 2026 | $3.43 | $3.60 | $3.41 | $3.49 | 330.65K |
| Jul 28, 2026 | $3.38 | $3.455 | $3.22 | $3.39 | 259.88K |
| Jul 27, 2026 | $3.50 | $3.5842 | $3.32 | $3.38 | 305.16K |
| Jul 24, 2026 | $3.48 | $3.60 | $3.33 | $3.47 | 313.37K |
| Jul 23, 2026 | $3.50 | $3.56 | $3.38 | $3.45 | 335.76K |
| Jul 22, 2026 | $3.84 | $3.87 | $3.50 | $3.50 | 494.25K |
| Jul 21, 2026 | $4.01 | $4.1499 | $3.835 | $3.845 | 310.77K |
| Jul 20, 2026 | $4.19 | $4.4573 | $3.92 | $4.00 | 339.11K |
| Jul 17, 2026 | $4.21 | $4.42 | $4.1401 | $4.175 | 413.76K |
| Jul 16, 2026 | $4.68 | $4.71 | $4.15 | $4.225 | 556.46K |
The latest Smart Investors Daily articles mentioning GALT.
GALT research
Company profile and research snapshot.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 17, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 2, 2025 | HC Wainwright & Co. | Neutral | — |
| Dec 27, 2024 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Feb 26, 2026
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader
SeekingAlpha · Dec 4, 2025
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis.
seekingalpha.com · Dec 4, 2025
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis. GALT reported a narrower Q3 loss due to lower R&D and operating expenses post-trial, with a cash runway through mid-2026 after securing a $10M credit line. Belapectin demonstrated reductions in liver stiffness, fibrogenesis, and new varices, especially in high-risk patients, while maintaining a favorable safety profile.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GALT.
